November 17, 2022
Article
The company says it plans to begin talking with regulators next year after seeing positive efficacy data in the trials.
November 16, 2022
Video
A clinician offers his perspective on what he sees as a clinician and trial investigator in terms of what is in the pipeline and both the encouraging data and uncertainty in therapy development overall.
Concerns of injectable HIV PrEP safety and efficacy demonstrate a need for health care providers to share reliable information with at-risk populations.
Three posters on the subject were presented at The Liver Meeting and were among the meeting’s key presentation highlights called “Best of the Liver Meeting.”
November 15, 2022
Although HIV PrEP uptake is gradually increasing, usage remains low among key at-risk populations.
Young women who binge drink, and especially those who use multiple substances, had a higher risk of COVID-19 infection and mental health complications.
One clinician discusses strategies in how his institution minimizes the wide spectrum approach to antibiotics as well as tries to prevent potential complications.
November 14, 2022
What are the characteristics and demographics of the chronic hepatitis B patients who develop severe outcomes?
An ICU hospitalist talks about his criteria and the treatment protocols for these cases.
Safety profile in this study showed the frequency of adverse reactions with these boosters were similar or lower than that of either a second or third dose of the original vaccine.
C difficile Awareness Month: Breakthroughs and Setbacks
C difficile, Antimicrobials, and the Patients Most Affected
European Commission Approves Sanofi-GSK COVID-19 Booster VidPrevtyn
Genetic Factors That Naturally Protect Against Severe COVID-19
